189 related articles for article (PubMed ID: 16611904)
1. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
Hossain MM; Parniak MA
J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.
Selhorst P; Vazquez AC; Terrazas-Aranda K; Michiels J; Vereecken K; Heyndrickx L; Weber J; Quiñones-Mateu ME; Ariën KK; Vanham G
Antimicrob Agents Chemother; 2011 Apr; 55(4):1403-13. PubMed ID: 21282453
[TBL] [Abstract][Full Text] [Related]
3. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.
Borkow G; Salomon H; Wainberg MA; Parniak MA
AIDS Res Hum Retroviruses; 2002 Jul; 18(10):711-4. PubMed ID: 12167278
[TBL] [Abstract][Full Text] [Related]
4. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
Borkow G; Barnard J; Nguyen TM; Belmonte A; Wainberg MA; Parniak MA
J Virol; 1997 Apr; 71(4):3023-30. PubMed ID: 9060662
[TBL] [Abstract][Full Text] [Related]
5. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
Borkow G; Arion D; Wainberg MA; Parniak MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
[TBL] [Abstract][Full Text] [Related]
6. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.
Motakis D; Parniak MA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1851-6. PubMed ID: 12019100
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.
Terrazas-Aranda K; Van Herrewege Y; Hazuda D; Lewi P; Costi R; Di Santo R; Cara A; Vanham G
Antimicrob Agents Chemother; 2008 Jul; 52(7):2544-54. PubMed ID: 18474579
[TBL] [Abstract][Full Text] [Related]
9. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
Liu S; Lu H; Neurath AR; Jiang S
Antimicrob Agents Chemother; 2005 May; 49(5):1830-6. PubMed ID: 15855503
[TBL] [Abstract][Full Text] [Related]
10. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
11. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
Barnard J; Borkow G; Parniak MA
Biochemistry; 1997 Jun; 36(25):7786-92. PubMed ID: 9201921
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
14. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
[TBL] [Abstract][Full Text] [Related]
16. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
18. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
19. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Balzarini J; Pelemans H; Esnouf R; De Clercq E
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):255-60. PubMed ID: 9491916
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Wildum S; Paulsen D; Thede K; Ruebsamen-Schaeff H; Zimmermann H
Antimicrob Agents Chemother; 2013 Nov; 57(11):5320-9. PubMed ID: 23959304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
